Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
DENVER, April 17, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) announced today that the Company will release its first quarter 2017 financial results on Thursday, May 4, 2017, before the opening of the U.S. financial markets.
Daniel E. Greenleaf, President and Chief Executive Officer, and Jeffrey M. Kreger, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:
| Date | Thursday, May 4, 2017 | |
| Time | 9:00 a.m. EDT | |
| Toll free (U.S.) | (888) 372-9592 | |
| Webcast (live and replay) | www.bioscrip.com | |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (US) and entering conference call ID number 8579499.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post-acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate-site settings. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Investor Contacts: Jeffrey M. Kreger Chief Financial Officer T: (720) 697-5200 [email protected] David Clair ICR, Inc. T: (646) 277-1266 [email protected]
